Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT06247280
Active, not recruiting Observational

Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR Mutation

NCT06247280 · tracked via the Priya Life Science South Korea tracker
Sponsor
Yuhan Corporation
Phase
Observational
Started
2022-06-24
Last updated
2024-12-06

Condition(s) studied

NSCLC

Study summary

Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR mutation to collect and analyze the patient's clinical features, diagnosis, and treatment results.

Eligibility

Sex
ALL
Min age
20 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Adults over 20-year-old with Korean nationality 2. A person who voluntarily signed the informed consent form for this study 3. All stage Non small cell lung cancer patients with EGFR mutation or Metastatic or recurred EGFR mutated NSCLC patients started with EGFR TKI treatment from 2021-01-01. Exclusion Criteria: 1. A person who is not confirmed NSCLC histologically or cytologically. 2. A person who doesn't consent to the study. 3. A person who is unable to complete the study judged by the investigator.

Primary outcome measure(s)

  • Clinical characteristics of NSCLC patients with EGFR mutation — 12months, 18months, 24months, 36months
    Analysis of clinical characteristics and clinical outcomes in NSCLC patients with EGFR mutation
  • Clinical outcome of NSCLS patients with EGFR mutation — 12months, 18months, 24months, 36months
    Analysis of clinical characteristics and clinical outcomes in NSCLC patients with EGFR mutation
  • PFS — 12months, 18months, 24months, 36months
    PFS underwent palliative therapy according to stages in NSCLC patients with EGFR mutation
  • DFS — 12months, 18months, 24months, 36months
    DFS in patients underwent definitive therapy according to stages in NSCLC patients with EGFR mutation

Trial sites (39)

FacilityCityRegionStatus
Kyungpook National University Chilgok Hospital Chilgok Daegu
Hallym Univ. Medical Center. Chuncheon Chuncheon Gangwon-do
Wonju Severance Christian Hospital Wŏnju Gangwon-do
Soon Chun Hyang University Hospital Bucheon Bucheon-si Gyeonggi-do
The Catholic University of Korea Uijeongbu St. Mary's Hospital Uijeongbu-si Gyeonggi-do
The Catholic Univ. of Korea Bucheon ST. Mary's Hospital Bucheon-si Gyeonggido
Wonkwang University Hospital Iksan Jeollabuk-do
Catholic Yeouido Sungmo Hospital Seoul Seoul
Inje University Haeundae Paik Hospital Busan South Korea
Kosin University Gospel Hospital Busan South Korea
Inje University Busan Paik Hospital Busan South Korea
Pusan National University Yangsan Hospital Busan South Korea
Samsung Changwon Hospital Busan South Korea
Changwon Gyeongsang National University Hospital Changwon South Korea
Yeungnam University Medical Center Daegu South Korea
Daegu Catholic University Medical Center Daegu South Korea
Keimyung University Dongsan Hospital Daegu South Korea
Chungnam National University Hospital Daejeon South Korea
Konyang Univ. Hospital Daejeon South Korea
Cheonnam National University Hwasun Hospital Hwasun South Korea
Inha University Hospital Incheon South Korea
The Catholic University of Korea Incheon St.Mary's Hospital Incheon South Korea
Pusan National University Hospital Pusan South Korea
Korea University Anam Hospital Seoul South Korea
The Catholic University of Korea, Eunpyeong St. Mary's Hospital Seoul South Korea
Samsung Medical Center Seoul South Korea
Chung-Ang University Hospital Seoul South Korea
Korea University Guro Hospital Seoul South Korea
Severance Hospital, Yonsei University Seoul South Korea
The Catholic University Of Korea Seoul St. Mary's Hospital Seoul South Korea
Asan Medical Center, University of Ulsan Seoul South Korea
Gangnam Severance Hospital Seoul South Korea
Hallym UNIV. Medical Center Seoul South Korea
Hanyang University Hospital Seoul South Korea
Inje University Sanggye Paik Hospital Seoul South Korea
Konkuk unversity hospital Seoul South Korea
Kyunghee university hospital Seoul South Korea
Soon Chun Hyang University Hospital Seoul Seoul South Korea
Yongin Severance Hospital Yongin South Korea

More Yuhan Corporation trials in South Korea

Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension Active, not recruiting
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors Recruiting
Clinical Trial to Evaluate the Safety and Efficacy of NTCB02-1 in Patients Who Require Parenteral Nutrition Recruiting
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946 Recruiting
Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension Active, not recruiting

Other trials for the same condition

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations Recruiting
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer Recruiting
Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients Active, not recruiting
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer Active, not recruiting
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06247280 on ClinicalTrials.gov ↗ ← All trials in South Korea